COVID-19 trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in COVID-19. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month7 studies across 4 companies, in the next 180 days.
August 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| IVVD | Invivyd, Inc. | Study of VYD2311 for the Prevention of COVID-19NCT07298434RT-PCR-confirmed symptomatic COVID-19 through Day 90 | Phase 3 | Active, not recruiting | Aug 2026 | ≤ 11 d | 2026-06-10 |
| IVVD | Invivyd, Inc. | Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 VaccineNCT07655180Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through day 6 | Phase 3 | Recruiting | Aug 2026 | ≤ 11 d | 2026-06-17 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NVAX | Novavax | Efficacy and Safety of NVX-CoV2705NCT07086222First episode of PCR-positive symptomatic COVID 19 | Phase 4 | Active, not recruiting | 2026-11-18 | in 90 d | 2026-05-08 |
December 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)NCT06613984observationalNumber of subjects with Solicited adverse events | — | Active, not recruiting | 2026-12-30 | in 132 d | 2026-01-14 |
| MRNA | ModernaTX, Inc. | A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsNCT06585241mRNA-1273.167, mRNA-1273.712, mRNA-1273.251, and mRNA-1273.261: Geometric Mean Value of Neutralizing Antibody Against COVID-19 Variants | Phase 4 | Recruiting | 2026-12-31 | in 133 d | 2026-03-27 |
January 2027 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | Korea Comirnaty Post-marketing SurveillanceNCT05032976observationalNumber of subjects with Solicited adverse events | — | Active, not recruiting | 2027-01-24 | in 157 d | 2026-04-23 |
| PFE | Pfizer | A Study to Look at the Health Outcomes of Patients With COVID-19 and InfluenzaNCT05160636observationalChange in Health Related Quality of Life (HRQoL) using EQ-5D-5L | — | Active, not recruiting | 2027-01-31 | in 164 d | 2026-03-31 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in COVID-19
most recently updated first328 studies match. Showing the first 100 of 328 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BNTX | BioNTech SE | — | A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy PeopleNCT06683352results2026-08-19Cohort 1: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination | Phase 1/2 | Completed | Biological: Investigational Influenza Vaccine, COVID-19 Vaccine, Licensed Influenza Vaccine 1, Licensed Influenza Vaccine 2 · Combination product: Investigational Influenza/COVID-19 Vaccine · Other: Placebo | Influenza,Human, COVID-19 | 1,353 | 2024-11-11 | 2025-07-15actual | — | 2026-08-19 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19NCT05386472Apparent Oral Clearance (CL/F) | Phase 1 | Terminatedsponsor's stated reason: The trial prematurely terminated due to the inability to recruit the planned number of subjects. The decision to terminate the trial was not based on any safety concerns. | Drug: nirmatrelvir, ritonavir | COVID-19 | 25 | 2022-06-22 | 2025-03-26actual | — | 2026-08-17 |
| PFE | Pfizer | $155.3B | A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe DiseaseNCT06679140Proportion of participants with COVID-19 related emergency department visits, all cause hospitalization and all cause mortality | Phase 3 | Recruiting | Drug: ibuzatrelvir, placebo | COVID-19 SARS-CoV-2 Infection | 2,330 | 2024-12-08 | 2027-10-03 | in 409 d | 2026-08-14 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely ImmunocompromisedNCT07013474The difference in the proportion of patients meeting the primary composite endpoint, between ibuzatrelvir and remdesivir vs remdesivir groups in symptomatic adult participants with COVID-19 who are severely immunocompromised | Phase 3 | Recruiting | Drug: ibuzatrelvir, remdesivir, placebo for ibuzatrelvir, placebo for remdesivir | COVID-19 Infection | 300 | 2025-07-14 | 2027-09-27 | in 403 d | 2026-08-14 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19NCT07089680observationalComposite outcome of progression to severe disease or all-cause mortality within 30 days | — | Completed | Drug: Nirmatrelvir/Ritonavir | Coronavirus Disease 2019 (COVID-19) | 937 | 2025-09-23 | 2026-05-29actual | — | 2026-08-14 |
| PFE | Pfizer | $155.3B | A Study on Paxlovid Once in the Market, to Observe Its Safety and Effectiveness in Patients Who Have a High Chance of Getting Severe COVID-19NCT05890612observationalProportion of patients with an adverse event (AE) | — | Recruiting | — | COVID-19 | 3,000 | 2023-11-29 | 2029-02-17 | in 912 d | 2026-08-12 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Baricitinib (LY3009104) in Children With COVID-19NCT05074420results2026-08-11Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC) of Baricitinib | Phase 3 | Terminatedsponsor's stated reason: Study terminated due to an inability to enroll participants. | Drug: Baricitinib | Covid19, Corona Virus Infection | 6 | 2021-12-21 | 2024-09-05actual | — | 2026-08-11 |
| BNTX | BioNTech SE | — | A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19NCT07222384Percentage of participants reporting local reactions | Phase 3 | Completed | Biological: BNT162b2 (2025/2026 formulation) | COVID-19, SARS-COV-2 Infection | 344 | 2025-10-30 | 2026-07-24actual | — | 2026-08-07 |
| BNTX | BioNTech SE | — | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of AgeNCT07730450Percentage of participants reporting local reactions or systemic events | Phase 4 | Recruiting | Biological: BNT162b2 Vaccine, Tdap Vaccine | COVID-19 Vaccines | 200 | 2026-07-23 | 2027-08-20 | in 365 d | 2026-08-07 |
| BNTX | BioNTech SE | — | A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy ChildrenNCT05543616Substudy A (SSA) - Ph 1 dose finding, percentage of participants reporting local reactions | Phase 3 | Completed | Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose | SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19 | 4,338 | 2022-09-23 | 2026-07-10actual | — | 2026-08-06 |
| ALGS | Aligos Therapeutics | $288M | A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic FunctionNCT06568861results2026-08-05Area Under the Concentration Time Curve [AUC] | Phase 1 | Completed | Drug: ALG-097558 | COVID-19 | 16 | 2025-01-13 | 2025-07-16actual | — | 2026-08-05 |
| 4507.T | Shionogi | $15.7B | Study of Secutrelvir in Participants With COVID-19NCT07746544Time to First Resolution of 14 Protocol-defined Symptoms of COVID-19 Through Day 21 | Phase 3 | Not yet recruiting | Drug: Secutrelvir, Placebo | COVID-19 | 1,200 | 2026-07-20 | 2027-07-31 | in 345 d | 2026-08-05 |
| 4507.T | Shionogi | $15.7B | A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe DiseaseNCT07743580Proportion of Participants Experiencing Any Component of the Following Composite Endpoint: Targeted Medically Attended Visits (tMAVs) Due to Worsening COVID-19, All-cause Hospitalizations, or All-cause Deaths | Phase 3 | Not yet recruiting | Drug: Secutrelvir, Placebo | SARS-CoV-2 | 2,000 | 2026-08-06 | 2028-06-30 | in 680 d | 2026-08-04 |
| PFE | Pfizer | $155.3B | A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of IbuzatrelvirNCT07552779Plasma ibuzatrelvir AUCinf (as data permit, otherwise AUClast) in the fasted state | Phase 1 | Completed | Drug: Ibuzatrelvir co-process API film coated tablet, Ibuzatrelvir filmcoated tablet | Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19), COVID-19 (Coronavirus Disease 2019), Upper Respiratory Tract Infections, Respiratory Tract Infection, Respiratory Tract Diseases, COVID-19, COVID-19 Infection, COVID-19 SARS-CoV-2 Infection, Pneumonia, Lung Diseases | 17 | 2026-04-13 | 2026-06-03actual | — | 2026-07-28 |
| PFE | Pfizer | $155.3B | Secondary Databased Post-marketing Surveillance Study of BNT162b2NCT06743334observationalFrequency of Adverse Events of Special Interest (AESI) - Measure of Occurrence | — | Completed | Biological: Tozinameran (BNT162b2), Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1), Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5) | COVID-19, SARS-CoV-2 | 14,302,529 | 2025-04-23 | 2025-05-28actual | — | 2026-07-10 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing FormulationsNCT07089706Subprotocol 1: Part A - Geometric Mean (GM) Value of Neutralizing Antibody (nAb) Against Vaccine-matched COVID-19 Variants | Phase 4 | Completed | Biological: mRNA-1283.251 Variant-containing Formulation | COVID-19 | 832 | 2025-07-21 | 2026-06-16actual | — | 2026-07-07 |
| PFE | Pfizer | $155.3B | Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims DataNCT05876377observationalAim 1: Any PCC-related diagnosis not present before the COVID-19 diagnosis | — | Completed | Biological: Pfizer-BioNTech COVID-19 mRNA vaccine | SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome | 1 | 2023-10-23 | 2026-05-31actual | — | 2026-06-30 |
| PFE | Pfizer | $155.3B | A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.NCT07261085observationalTime to the first severe composite outcome (all-cause hospital admission, ICU admission, or death) within 30 days of treatment assessment. | — | Completed | Drug: nirmatrelvir-ritonavir · Other: No treatment | COVID-19 | 99,000 | 2025-10-27 | 2026-02-26actual | — | 2026-06-29 |
| VXRT | Vaxart | $124M | A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 InfectionNCT06672055KP.2 Cohorts: Percentage of Participants with First Occurrence of Symptomatic Polymerase Chain Reaction (PCR)-Positive COVID-19 at 14 Days Post-vaccination | Phase 2 | Active, not recruiting | Biological: VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3 | SARS-CoV2, COVID-19 | 5,485 | 2024-10-08 | May 2027 | ≤ 284 d | 2026-06-25 |
| PFE | Pfizer | $155.3B | A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.NCT06085924observationalCohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Required Intensive Care Unit (ICU) | — | Completed | Drug: SoC · Other: Disease description | COVID-19 | 2,315,187 | 2023-11-07 | 2025-02-28actual | — | 2026-06-22 |
| AZN | AstraZeneca | — | Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)NCT05648110results2026-06-18(Main Cohort) Occurrence of AEs Collected Through Approximately 90 Days After Each IMP Administration; SAEs, MAAEs, and AESIs Collected Through Day 451 | Phase 2/3 | Completed | Biological: AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152 | COVID-19, SARS-CoV-2 | 3,882 | 2022-12-16 | 2024-03-29actual | — | 2026-06-18 |
| IVVD | Invivyd, Inc. | $256M | Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 VaccineNCT07655180Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through day 6 | Phase 3 | Recruiting | Drug: COVID-19 mRNA vaccine, VYD2311, Placebo (Normal Saline) | COVID-19 | 210 | 2026-06-08 | Aug 2026 | ≤ 11 d | 2026-06-17 |
| IVVD | Invivyd, Inc. | $256M | Study of VYD2311 for the Prevention of COVID-19NCT07298434RT-PCR-confirmed symptomatic COVID-19 through Day 90 | Phase 3 | Active, not recruiting | Drug: VYD2311-SD, VYD2311-MD, Placebo | COVID-19 | 1,770 | 2026-01-08 | Aug 2026 | ≤ 11 d | 2026-06-10 |
| NVAX | Novavax | $1.3B | A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination VaccineNCT06291857Numbers of participants with solicited local and systemic adverse events (AEs) | Phase 3 | Completed | Biological: CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, Novavax COVID-19 Vaccine, tNIV Vaccine, Fluzone High Dose | COVID-19 | 9,320 | 2024-12-09 | 2025-12-24actual | — | 2026-06-05 |
| SNY | Sanofi | — | Safety and Immunogenicity of NVX-CoV2705NCT07079670Pseudovirus neutralization (ID50) of Omicron JN.1 subvariant vaccine expressed as GMFR | Phase 3 | Completed | Biological: NVX-CoV2705 | COVID-19, SARS-CoV-2 Infection | 676 | 2025-10-09 | 2026-01-12actual | — | 2026-06-05 |
| NVAX | Novavax | $1.3B | Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United StatesNCT06633835Percentage of participants with solicited systemic reactogenicity symptoms. | Phase 4 | Completed | Biological: protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine | COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection | 660 | 2024-09-19 | 2024-12-30actual | — | 2026-06-02 |
| BNTX | BioNTech SE | — | A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 YearsNCT07069309Percentage of participants reporting local reactions | Phase 3 | Completed | Biological: BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) | COVID-19, SARS-COV-2 Infection | 774 | 2025-07-08 | 2026-05-01actual | — | 2026-06-01 |
| BNTX | BioNTech SE | — | Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy ChildrenNCT04816643results2026-05-28Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of Age | Phase 3 | Completed | Biological: Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg, BNT162b2 30mcg, Biological/Vaccine: BNT162b2 3mcg · Other: Placebo | SARS-CoV-2 Infection, COVID-19 | 11,837 | 2021-03-24 | 2023-10-04actual | — | 2026-05-28 |
| NVAX | Novavax | $1.3B | Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 YearsNCT05468736Reactogenicity Incidence and Severity | Phase 2/3 | Completed | Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period) · Other: Placebo | COVID-19 | 3,600 | 2022-07-22 | 2024-01-16actual | — | 2026-05-22 |
| INMB | Inmune Bio, Inc. | $59M | INB03 for the Treatment of Pulmonary Complications From COVID-19NCT04370236results2026-05-19Cochran-Mantel-Haenszel Analysis of Proportion of Patients With Disease Progression | Phase 2/3 | Terminatedsponsor's stated reason: Futility | Drug: INB03, Placebo | COVID-19 | 79 | 2020-10-21 | 2021-10-13actual | — | 2026-05-19 |
| NVAX | Novavax | $1.3B | Efficacy and Safety of NVX-CoV2705NCT07086222First episode of PCR-positive symptomatic COVID 19 | Phase 4 | Active, not recruiting | Biological: NVX-CoV2705, Placebo | COVID-19, Sars-CoV-2 Infection | 6,500 | 2025-11-20 | 2026-11-18 | in 90 d | 2026-05-08 |
| SNY | Sanofi | — | Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and OlderNCT06695117Number of participants with immediate adverse events (AEs) | Phase 1/2 | Completed | Biological: IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1), IIV-HD + rC19 (dose 2), IIV-HD + rC19 (dose 3), IIV-HD + rC19 (dose 4) · Other: Placebo (0.9% NaCl) | COVID-19 Immunization, Influenza Immunization | 980 | 2024-11-19 | 2026-04-16actual | — | 2026-05-05 |
| SNY | Sanofi | — | Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and OlderNCT06695130Number of participants with immediate adverse events (AEs) | Phase 1/2 | Completed | Biological: RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1), RIV + rC19 (dose 2), RIV + rC19 (dose 3), RIV + rC19 (dose 4) · Other: Placebo (0.9% NaCl) | COVID-19 Immunization, Influenza Immunization | 980 | 2024-11-18 | 2026-04-03actual | — | 2026-05-05 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19NCT05815498results2026-05-01Part 1: Geometric Mean (GM) of Omicron BA.4/5 at Day 29 | Phase 3 | Completed | Biological: mRNA-1283.222, mRNA-1273.222, mRNA-1283.815, mRNA-1273.815 | COVID-19 | 13,553 | 2023-03-28 | 2025-04-12actual | — | 2026-05-01 |
| BNTX | BioNTech SE | — | A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy IndividualsNCT05997290results2026-04-28Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSA | Phase 2/3 | Completed | Biological: BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2) | SARS-CoV-2 Infection, COVID-19 | 1,051 | 2023-08-10 | 2025-03-13actual | — | 2026-04-28 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)NCT07266558VE of mRNA-1273 (Variant Formulation) to Prevent the First Event of Symptomatic COVID-19 after Study Injection | Phase 4 | Active, not recruiting | Biological: mRNA-1273, mRNA-1283, Placebo | SARS-CoV-2 | 30,000 | 2025-11-26 | 2027-06-16 | in 300 d | 2026-04-28 |
| PFE | Pfizer | $155.3B | Korea Comirnaty Post-marketing SurveillanceNCT05032976observationalNumber of subjects with Solicited adverse events | — | Active, not recruiting | Biological: Tozinameran 12 Years of age and older, Tozinameran 5 to 11 Years of age, Tozinameran 6 months to 4 years of age, Riltozinameran 12 Years of age and older, Famtozinameran 12 Years of age and older, Famtozinameran 5 to 11 Years of age, Raxtozinameran 12 years of age and older, Raxtozinameran 6 months to 4 years of age | COVID-19, Vaccines, Adverse Effects, SARS-CoV-2, Safety | 12,000 | 2022-03-18 | 2027-01-24 | in 157 d | 2026-04-23 |
| CRDL | Cardiol Therapeutics Inc. | $190M | Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk FactorsNCT04615949results2025-07-25Composite of All-cause Mortality, Requirement for ICU Admission and/or Ventillatory Support and Cardiovascular Complications | Phase 2/3 | Terminatedsponsor's stated reason: The changing nature of COVID-19 including a more vaccinated population, increasing natural population immunity, milder variants and other related factors has meant that it is no longer realistic to recruit the patients in a reasonable time frame. | Drug: Cannabidiol, pharmaceutically produced with < 5 ppm THC, Placebo | COVID-19, Cardiovascular Diseases, Cardiovascular Risk Factor | 90 | 2021-04-30 | 2022-11-30actual | — | 2026-04-21 |
| NVAX | Novavax | $1.3B | Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in AdultsNCT05463068results2026-04-17Serum Immunoglobulin G (IgG) Antibody Levels to the SARS-CoV-2 Spike Protein Expressed as Geometric Mean ELISA Unit [GMEUs] | Phase 3 | Completed | Drug: NVX-Cov2373 | COVID-19, SARS-CoV-2 Infection | 911 | 2022-07-11 | 2022-08-17actual | — | 2026-04-17 |
| MRNA | ModernaTX, Inc. | $25.1B | Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGENCT06333704observationalNumber of Participants With AEs | — | Active, not recruiting | Biological: SPIKEVAX Bivalent BA.1, SPIKEVAX Bivalent BA.4/5, SPIKEVAX XBB.1.5, SPIKEVAX JN.1 | SARS-CoV-2 | 4,207 | 2023-03-10 | 2029-03-29 | in 952 d | 2026-04-16 |
| BNTX | BioNTech SE | — | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of AgeNCT07300839Percentage of participants reporting local reactions or systemic events | Phase 3 | Active, not recruiting | Biological: BNT162b2 Vaccine, Placebo | COVID-19, SARS-COV-2 Infection | 5,240 | 2025-12-10 | 2026-07-31 | — | 2026-04-13 |
| PFE | Pfizer | $155.3B | A Study to Look at the Health Outcomes of Patients With COVID-19 and InfluenzaNCT05160636observationalChange in Health Related Quality of Life (HRQoL) using EQ-5D-5L | — | Active, not recruiting | Biological: COVID-19 Vaccine | COVID-19, Coronavirus Disease 2019, Influenza | 999 | 2022-01-31 | 2027-01-31 | in 164 d | 2026-03-31 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsNCT06585241mRNA-1273.167, mRNA-1273.712, mRNA-1273.251, and mRNA-1273.261: Geometric Mean Value of Neutralizing Antibody Against COVID-19 Variants | Phase 4 | Recruiting | Biological: mRNA-1273 Variant-containing Formulation | SARS-CoV-2 | 1,144 | 2024-09-09 | 2026-12-31 | in 133 d | 2026-03-27 |
| BNTX | BioNTech SE | — | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy IndividualsNCT04368728results2026-03-25Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 1 | Phase 2/3 | Completed | Biological: BNT162b1, BNT162b2, BNT162b2SA · Other: Placebo | SARS-CoV-2 Infection, COVID-19 | 46,969 | 2020-04-29 | 2023-02-10actual | — | 2026-03-25 |
| BNTX | BioNTech SE | — | Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy PopulationNCT04649021SARS-CoV-2 serum neutralizing titers - Seroconversion rates (SCR) | Phase 2 | Completed | Biological: BNT162b2 · Other: Placebo | SARS-CoV-2 | 960 | 2020-12-04 | 2021-02-07actual | — | 2026-03-20 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of Modified mRNA Vaccines in Healthy AdultsNCT05397223Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) | Phase 1 | Completed | Biological: mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647 | SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus | 308 | 2022-05-24 | 2026-02-27actual | — | 2026-03-12 |
| HRTX | Heron Therapeutics | $57M | Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)NCT04470622results2022-08-30Proportion of Subjects Alive and Discharged From the Hospital. | Phase 2 | Terminatedsponsor's stated reason: Study was terminated early by Heron, and was not terminated for safety reasons. | Drug: Aprepitant injectable emulsion, Saline Placebo | COVID-19 | 27 | 2020-07-20 | 2021-04-09actual | — | 2026-03-02 |
| PFE | Pfizer | $155.3B | A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming SevereNCT07072793results2026-01-12observationalNumber of Participants According to Age Group: Unmatched Participants | — | Completed | Drug: nirmatrelvir-ritonavir | COVID-19 (Coronavirus Disease 2019) | 131,005 | 2024-10-31 | 2024-11-15actual | — | 2026-02-09 |
| BNTX | BioNTech SE | — | A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy PeopleNCT06821061Percentage of participants reporting prompted local reactions within 7 days following investigational product administration | Phase 1/2 | Completed | Biological: Investigational Influenza Vaccine, Investigational COVID-19 Vaccine, Licensed Influenza Vaccine 1, Licensed Influenza Vaccine 2, Licensed Influenza Vaccine 3, Licensed COVID-19 Vaccine · Combination product: Investigational Influenza and COVID-19 Combination Vaccine | Influenza, COVID-19 (Coronavirus Disease 2019) | 2,650 | 2025-02-10 | 2025-12-17actual | — | 2026-01-26 |
| PFE | Pfizer | $155.3B | Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)NCT06613984observationalNumber of subjects with Solicited adverse events | — | Active, not recruiting | Biological: Bretovameran | COVID-19 Vaccination | 660 | 2024-10-11 | 2026-12-30 | in 132 d | 2026-01-14 |
| BNTX | BioNTech SE | — | Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy PeopleNCT05541861results2026-01-13Number of Participants With Solicited Local Reactions- Post Dose 1 | Phase 1 | Completed | Biological: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT162b4 5 mcg, BNT162b4 10 mcg, BNT162b4 15 mcg, BNT162b4 30 mcg, BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg | SARS-CoV-2 Infection, COVID-19 | 383 | 2022-11-08 | 2024-11-22actual | — | 2026-01-13 |
| AZN | AstraZeneca | — | Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)NCT05687877observationalIncidence of ADRs | — | Completed | — | SARS-CoV-2 Infection | 366 | 2023-01-06 | 2025-01-20actual | — | 2026-01-08 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy AdultsNCT05827926results2025-12-23Parts 1 and 2: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) | Phase 1/2 | Completed | Biological: Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2, mRNA-1083.3, Investigational Influenza Vaccine 1, Investigational COVID-19 Vaccine 1, COVID-19 Vaccine 1, Investigational Influenza Vaccine 2, Influenza Vaccine 2, mRNA-1083, Investigational COVID-19 Vaccine 2, COVID-19 Vaccine 2 | SARS-CoV-2, Influenza | 1,758 | 2023-04-14 | 2024-12-03actual | — | 2025-12-23 |
| ARCT | Arcturus Therapeutics, Inc. | $233M | Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in AdultsNCT06279871results2025-12-12Groups 2a and 2b and ARCT-154-J01 Historical Control: Geometric Mean Titers (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody Titers Against Omicron XBB.1.5 Subvariant at Day 29 | Phase 3 | Completed | Biological: ARCT-2303, Influenza vaccine, Influenza vaccine, adjuvanted · Other: Placebo | COVID-19 | 1,514 | 2024-03-27 | 2024-10-09actual | — | 2025-12-12 |
| BNTX | BioNTech SE | — | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.NCT06178991results2025-12-04Cohort 1: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination in Investigational Vaccine Extremity | Phase 3 | Completed | Biological: Influenza and COVID-19 Combination A, Licensed influenza vaccine, COVID-19 Vaccine, Influenza and COVID-19 Combination B, Placebo, Investigational influenza vaccine | Influenza, COVID-19 | 8,795 | 2023-12-20 | 2024-11-26actual | — | 2025-12-04 |
| MRNA | ModernaTX, Inc. | $25.1B | Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of AgeNCT06694389Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) Assay | Phase 3 | Completed | Biological: mRNA-1083, Licensed Influenza Vaccine, SARS-CoV-2 Vaccine · Other: Placebo | COVID-19, Influenza | 2,457 | 2024-11-18 | 2025-11-17actual | — | 2025-12-02 |
| 4507.T | Shionogi | $15.7B | A Study of S-268019 for the Prevention of COVID-19NCT05212948results2025-11-28Number of Participants With First Occurrence of SARS-CoV-2 Reverse Transcription Polymerase Chain Reaction (RT-PCR)-Positive Symptomatic COVID-19 With Onset at Least 14 Days Following Second Vaccination During the Initial Vaccination Period | Phase 3 | Completed | Drug: S-268019-b, Placebo | SARS-CoV-2 | 9,902 | 2021-12-25 | 2022-12-19actual | — | 2025-11-28 |
| ABVX | Abivax S.A. | — | ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19NCT04393038results2025-11-26Rate of Responders: i.e. Rate of Patients Who do Not Require Use of High-flow Oxygen Invasive or Non-invasive Mechanical Ventilation (IMV and NIV, Respectively) Within 28 Days and Who Are Alive at the End of the 28 Days Period. | Phase 2/3 | Terminatedsponsor's stated reason: Interim analysis concludes that the study is futile | Drug: ABX464, Placebo | COVID-19 | 509 | 2020-07-01 | 2021-03-05actual | — | 2025-11-26 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of AgeNCT05436834Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) | Phase 3 | Completed | Biological: mRNA-1273.214, mRNA-1273.815 | SARS-CoV-2 | 1,807 | 2022-06-21 | 2025-10-20actual | — | 2025-11-26 |
| MRNA | ModernaTX, Inc. | $25.1B | Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in InfantsNCT05584202results2025-11-26Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After First Injection | Phase 2 | Terminatedsponsor's stated reason: The trial was terminated because data from the dose finding part of the trial did not support further evaluation of effectiveness of mRNA-1273. There were no safety concerns. | Biological: mRNA-1273.214 · Other: Placebo | SARS-CoV-2 | 68 | 2022-09-30 | 2024-11-15actual | — | 2025-11-26 |
| PFE | Pfizer | $155.3B | A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19NCT06923137observationalCOVID-19 outpatient encounter in adults | — | Active, not recruiting | Drug: BNT162b2 | COVID-19 SARS-CoV-2 Infection, COVID-19, COVID-19 Infection, Coronavirus Disease 2019 (COVID-19), COVID-19 (Coronavirus Disease 2019), COVID-19 Vaccination, COVID-19 Vaccines, SARS-CoV-2 Infection, COVID19, SARS-CoV-2 Infection, COVID-19 | 1 | 2025-04-16 | 2030-10-31 | in 1,533 d | 2025-11-19 |
| BNTX | BioNTech SE | — | To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.NCT04955626results2025-11-10SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population | Phase 3 | Completed | Biological: BNT162b2, BNT162b2 OMI, Combination BNT162b2 and BNT162b2 OMI, Combination (Bivalent) BNT162b2 and BNT162b2 OMI · Other: Placebo | SARS-CoV-2 Infection, COVID-19 | 16,372 | 2021-07-01 | 2023-05-25actual | — | 2025-11-10 |
| PFE | Pfizer | $155.3B | Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 VaccineNCT06703190observationalNumber of Pfizer/BioNTech 2024-2025 formulation vaccinated patients who test positive for SARS-CoV-2 ≥14 days after receipt of vaccine | — | Terminatedsponsor's stated reason: This secondary data analysis of symptomatic CVS MinuteClinics patients testing for SARS-CoV-2 was terminated due to incomplete data on KP.2 vaccination status (exposure). Termination was not based on any safety concerns or regulatory requirements. | Biological: Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated, Not vaccinated with 2024-2025 formulated COVID-19 vaccine | COVID-19 | 1 | 2024-11-25 | 2025-06-06actual | — | 2025-11-06 |
| REGN | Regeneron Pharmaceuticals | $76.1B | COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe DiseaseNCT05081388results2024-04-26Treatment Emergent Adverse Events (TEAEs) | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: REGN14256, imdevimab, casirivimab + imdevimab, Placebo | SARS-CoV-2 | 25 | 2021-11-08 | 2022-06-30actual | — | 2025-10-28 |
| REGN | Regeneron Pharmaceuticals | $76.1B | COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of AgeNCT04992273results2023-03-06Concentrations of Casirivimab+Imdevimab in Serum Over Time. | Phase 2 | Terminatedsponsor's stated reason: Emerging SARS-CoV-2 variants impacting susceptibility to study drug | Drug: casirivimab+imdevimab | COVID-19 | 7 | 2021-09-13 | 2022-06-01actual | — | 2025-10-20 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of AgeNCT06864143Geometric Mean Titer (GMT) as Measured by Hemagglutination Inhibition (HAI) Assay for Influenza | Phase 2 | Completed | Biological: mRNA-1083 Composition 1 Dose A Lot A, mRNA-1083 Composition 1 Dose A Lot B, mRNA-1083 Composition 1 Dose B, mRNA-1083 Composition 1 Dose C, mRNA-1083 Composition 2 Dose A, mRNA-1083 Composition 2 Dose B, mRNA-1083 Composition 3 Dose A, mRNA-1083 Composition 3 Dose B, Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza Vaccine, Investigational COVID-19 Vaccine Lot A, Investigational COVID-19 Vaccine Lot B | Influenza, SARS-CoV-2 | 1,320 | 2025-03-07 | 2025-10-13actual | — | 2025-10-20 |
| ARCT | Arcturus Therapeutics, Inc. | $233M | A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy AdultsNCT05037097results2025-10-15Number of Participants Reporting Solicited Local or Systemic Adverse Events (AEs) | Phase 1/2 | Completed | Biological: ARCT-165, ARCT-154, ARCT-021 | COVID-19, SARS-CoV-2 Infection, Corona Virus Infection | 72 | 2021-08-30 | 2023-12-19actual | — | 2025-10-15 |
| REGN | Regeneron Pharmaceuticals | $76.1B | COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19NCT05092581Concentrations of casirivimab+imdevimab in serum over time | Phase 1 | Terminatedsponsor's stated reason: Emerging SARS-CoV-2 variants impacting susceptibility to study drug | Drug: casirivimab+imdevimab | COVID-19 | 2 | 2021-12-16 | 2022-06-09actual | — | 2025-10-14 |
| MRNA | ModernaTX, Inc. | $25.1B | A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)NCT06508320Geometric Mean Value of Antibodies at Day 29, as Measured by Hemagglutinin Inhibition (HAI) Assay for Influenza | Phase 2 | Completed | Biological: mRNA-1083 | Influenza, SARS-CoV-2 | 932 | 2024-07-15 | 2025-09-25actual | — | 2025-10-14 |
| BNTX | BioNTech SE | — | A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy IndividualsNCT05472038results2025-10-01Cohort 1: Percentage of Participants Reporting Local Reactions Within 7 Days After Study Vaccination | Phase 2/3 | Completed | Biological: BNT162b5 Bivalent (WT/OMI BA.2), BNT162b2 Bivalent (WT/OMI BA.1), BNT162b2 Bivalent (WT/OMI BA.4/BA.5), BNT162b5 Bivalent (Original/OMI BA.4/BA.5), BNT162b6 Bivalent (Original/OMI BA.4/BA.5), BNT162b7 Bivalent (Original/OMI BA.4/BA.5), BNT162b7 Monovalent (OMI BA.4/BA.5) | SARS-CoV-2 Infection, COVID-19 | 1,453 | 2022-07-26 | 2024-03-26actual | — | 2025-10-01 |
| PFE | Pfizer | $155.3B | A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy AdultsNCT06237049results2025-09-30Percentage of Participants Who Reported Any Local Reaction up to 7 Days Following Vaccination | Phase 2 | Completed | Biological: BNT162b2 (Omi XBB.1.5)/RIV, BNT162b2 (Omi XBB.1.5), RIV · Other: Normal saline placebo | Influenza, Human, SARS-CoV-2 Infection, COVID-19 | 644 | 2024-01-31 | 2024-09-13actual | — | 2025-09-30 |
| 4507.T | Shionogi | $15.7B | A Study of S-892216 in Participants With COVID-19NCT06928051Change From Baseline in SARS-CoV-2 Viral RNA Level on Day 4 as Assessed by Quantitative Reverse-transcription Polymerase Chain Reaction (qRT-PCR) of Nasopharyngeal (NP) Swabs | Phase 2 | Completed | Drug: S-892216, Placebo | COVID-19 | 282 | 2025-06-06 | 2025-09-22actual | — | 2025-09-30 |
| AZN | AstraZeneca | — | Covid-19 Data Analyses in BrazilNCT06652451observationalHospitalization | — | Completed | — | Covid | 361,000 | 2024-11-12 | 2024-11-29actual | — | 2025-09-18 |
| 4507.T | Shionogi | $15.7B | A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19NCT05305547Median Time to Sustained Symptom Resolution | Phase 3 | Completed | Drug: S-217622, Placebo | SARS-CoV-2 Infection | 2,093 | 2022-08-03 | 2024-01-07actual | — | 2025-09-16 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19NCT04649151results2025-09-15Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) | Phase 2/3 | Completed | Biological: mRNA-1273, Placebo, mRNA-1273.222 | SARS-CoV-2 | 4,328 | 2020-12-09 | 2024-06-14actual | — | 2025-09-15 |
| PFE | Pfizer | $155.3B | Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims DataNCT06199934results2025-09-10observationalNumber of Participants COVID-19 Diagnosis | — | Completed | Biological: Vaccination | SARS-CoV-2, COVID-19 Vaccines | 19,853,610 | 2023-09-11 | 2024-07-31actual | — | 2025-09-10 |
| PFE | Pfizer | $155.3B | A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19NCT05263908results2025-09-03observationalIncidence of Adverse Drug Reactions | — | Completed | Drug: nirmatrelvir / ritonavir | SARS-CoV-2 Infection | 3,346 | 2022-03-31 | 2023-07-10actual | — | 2025-09-03 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.NCT06291831results2025-08-19observationalNumber of Participants Classified Based on Education | — | Completed | Drug: nirmatrelvir, ritonavir · Other: Controls | COVID-19 | 3,011 | 2024-03-13 | 2024-05-14actual | — | 2025-08-19 |
| AZN | AstraZeneca | — | Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19NCT06057064results2025-08-15The Number and Proportion of Subjects With AEs, SAEs, MAAEs, AESIs. | Phase 2 | Completed | Biological: Biological: AZD3152, Biological: Placebo | COVID-19, SARS-CoV-2 | 116 | 2023-09-29 | 2024-05-17actual | — | 2025-08-15 |
| 4507.T | Shionogi | $15.7B | Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 InfectionNCT05897541Number of Participants in the Modified Intention-to-treat (mITT) Population with a Negative Screening SARS-CoV-2 Infection who are Infected with SARS-CoV-2 and Have COVID-19 Symptoms Onset | Phase 3 | Completed | Drug: S-217622, Placebo | SARS-CoV-2 Infection | 2,387 | 2023-06-09 | 2024-08-30actual | — | 2025-08-06 |
| RDHL | RedHill Biopharma Limited | — | Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 PneumoniaNCT04467840results2023-10-19Supplemental Oxygen Requirement | Phase 2/3 | Completed | Drug: Opaganib, Placebo | COVID-19, Lung Infection | 475 | 2020-08-21 | 2021-07-18actual | — | 2025-07-31 |
| PFE | Pfizer | $155.3B | Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern CaliforniaNCT04848584observationalTest Negative Design Outcome: VE calculated as 1 minus the odds ratio (OR) comparing the odds of being vaccinated with 2 doses with BNT162b2 for hospitalized cases and controls, multiplied by 100%. | — | Completed | Biological: Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 BA.4/5 bivalent, XBB.1.5-adapted vaccinated | COVID-19 | 1 | 2021-05-15 | 2025-04-30actual | — | 2025-07-29 |
| PFE | Pfizer | $155.3B | A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.NCT07090486observationalCardio-pulmonary Measurement A: Change in rate of cardiopulmonary-related healthcare utilization in patients that received nirmatrelvir-ritonavir compared to not received. | — | Completed | Drug: nirmatrelvir-ritonavir | COVID-19 | 14,000 | 2025-04-15 | 2025-04-15actual | — | 2025-07-29 |
| BNTX | BioNTech SE | — | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and InfluenzaNCT05596734results2025-07-23SSA: Percentage of Participants With Local Reactions up to 7 Days Following Vaccination (18-64 Years) | Phase 2 | Completed | Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5), qIRV (22/23), QIV, bIRV, tIRV | Influenza, Human, COVID-19 | 1,019 | 2022-10-28 | 2023-12-28actual | — | 2025-07-23 |
| IMNN | Imunon | $9M | Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2NCT06283459Number of participants with local and systemic reactogenicity adverse events and all adverse events | Phase 1/2 | Completed | Biological: IMNN-101 | SARS CoV 2 Infection | 24 | 2024-06-04 | 2025-03-07actual | — | 2025-07-23 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine BoostersNCT05137236results2025-07-17Parts A and B: Number of Participants With Solicited Local and Solicited Systemic Reactogenicity Adverse Reactions (ARs) | Phase 2 | Completed | Biological: mRNA-1283, mRNA-1283.211, mRNA-1273, mRNA-1283.529 | SARS-CoV-2 | 540 | 2021-12-06 | 2023-03-23actual | — | 2025-07-17 |
| PFE | Pfizer | $155.3B | EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe DiseaseNCT05261139Cohort 1-2: Maximum Observed Plasma Concentration (Cmax) of nirmatrelvir and ritonavir | Phase 3 | Recruiting | Drug: nirmatrelvir, ritonavir | COVID-19 | 160 | 2022-03-07 | 2026-07-30 | — | 2025-07-17 |
| NVAX | Novavax | $1.3B | Phase 3 Adolescent Study for SARS-CoV-2 rS Variant VaccinesNCT05973006results2025-07-15Participants With Solicited Local and Systemic AEs for 7 Days Following Vaccination | Phase 3 | Completed | Biological: NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg) | COVID-19 | 400 | 2023-08-16 | 2024-04-01actual | — | 2025-07-15 |
| PFE | Pfizer | $155.3B | Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 YearsNCT06130410results2025-07-14observationalProportion of Participants With Adverse Reaction (AR) | — | Completed | Biological: COMIRNATY intramuscular injection | SARS-CoV-2, COVID-19 | 25 | 2024-03-06 | 2024-07-26actual | — | 2025-07-14 |
| PFE | Pfizer | $155.3B | EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19NCT04960202results2023-02-09Percentage of Participants With Covid-19 Related Hospitalization or Death From Any Cause Through Day 28- Modified Intent-To-Treat (mITT) Population | Phase 2/3 | Completed | Drug: PF-07321332, Ritonavir, Placebo | COVID-19 | 2,091 | 2021-07-16 | 2021-12-09actual | — | 2025-07-10 |
| GENB | Generate Biomedicines | $2.0B | Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult ParticipantsNCT07050511To assess the safety and tolerability of a single ascending dose of GB-0669 administered intravenously in healthy volunteers | Phase 1 | Completed | Drug: GB-0669, Placebo | SARS CoV-2 | 51 | 2023-07-18 | 2024-11-22actual | — | 2025-07-03 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of AgeNCT06097273results2025-06-13Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) Assay | Phase 3 | Completed | Biological: mRNA-1083, Placebo, Influenza Vaccine, COVID-19 Vaccine | SARS-CoV-2, Influenza | 8,061 | 2023-10-19 | 2024-05-28actual | — | 2025-07-01 |
| AZN | AstraZeneca | — | Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council CountriesNCT05315323observationalDemographics | — | Completed | — | COVID-19 | 550 | 2022-06-23 | 2024-06-27actual | — | 2025-06-29 |
| AZN | AstraZeneca | — | A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19NCT06147063Incidence of immediate unsolicited adverse events (AE) | Phase 1 | Completed | Biological: AZD9838, Licensed mRNA vaccine, AZD6563 | COVID-19, SARS-CoV-2 Infection | 243 | 2023-11-27 | 2024-04-30actual | — | 2025-06-29 |
| NVAX | Novavax | $1.3B | Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA VaccinesNCT05875701results2025-06-26Neutralizing Antibody (Nab) for SARS-CoV-2 Wildtype Virus (Wuhan) Responses Expressed as Geometric Mean Titers (GMT) | Phase 3 | Completed | Biological: NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant | COVID-19 | 147 | 2023-03-28 | 2023-11-11actual | — | 2025-06-26 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of AgeNCT04796896results2025-06-13Parts 1, 2, and 3: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) | Phase 2/3 | Completed | Biological: mRNA-1273, Placebo, mRNA-1273.214 | SARS-CoV-2 | 11,942 | 2021-03-15 | 2024-03-15actual | — | 2025-06-13 |
| AVIR | Atea Pharmaceuticals, Inc. | $423M | SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19NCT05629962results2025-06-13Percentage of Subjects Hospitalized for Any Cause or Died Due to Any Cause | Phase 3 | Completed | Drug: Bemnifosbuvir (BEM), Placebo | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19 | 2,285 | 2022-11-25 | 2024-04-25actual | — | 2025-06-13 |
| EBS | Emergent BioSolutions | $239M | A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy AdultsNCT04661839results2023-02-02Subjects With Adverse Events (AEs) up to 3 Days Post-dosing | Phase 1 | Completed | Biological: COVID-HIGIV · Other: Placebo (saline) | COVID-19 | 28 | 2020-12-24 | 2021-07-27actual | — | 2025-06-08 |
| EBS | Emergent BioSolutions | $239M | A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected AdultsNCT05142306results2024-05-20Participants With Adverse Events (AEs) up to 72 Hours Post-dosing | Phase 1 | Completed | Biological: COVID-HIG | SARS-CoV-2 Infection | 23 | 2021-12-07 | 2022-03-28actual | — | 2025-06-08 |
| AZN | AstraZeneca | — | Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response StudyNCT05872958Number of participants with adverse event | Phase 1 | Completed | Drug: AZD3152 · Other: Placebo | COVID-19 | 98 | 2023-05-19 | 2024-08-20actual | — | 2025-06-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How COVID-19 is matched — 25 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- COVID-19
- SARS-CoV-2
- SARS-CoV-2 Infection
- Covid19
- Coronavirus Disease 2019 (COVID-19)
- COVID
- COVID-19, SARS-CoV-2
- COVID-19 (Coronavirus Disease 2019)
- COVID-19 Infection
- SARS CoV 2 Infection
- SARS-CoV2
- COVID-19 SARS-CoV-2 Infection
- COVID-19 Vaccines
- Coronavirus Disease (COVID-19)
- SARS-CoV2 Infection
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- Acute Lung Injury (ALI) Associated With COVID-19
- COVID-19 Immunization
- COVID-19 Vaccination
- Prevention of Infectious Disease Caused by SARS-CoV-2
- SARS CoV-2
- SARS-CoV 2
- SARS-CoV-2 Infection, COVID-19
- SARS-CoV-2 Infection, COVID19
- SARS-CoV-2, COVID-19
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “COVID-19” (a text search, wider than this page)